Want to join the conversation?
Pharmaceutical company $ALXN delivered total YoverY revenue growth of 18% and volume growth of 23% in 2Q16, driven by the strength of its three marketed therapies. Soliris grew with a steady number of new patients with PNH and aHUS being treated globally. Strensiq is a new driver of growth and Kanuma continued to progress.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?